599P A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment
2010 ◽
Vol 17
(4)
◽
pp. 880-887
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 4669-4669
2020 ◽
2010 ◽
Vol 103
(4)
◽
pp. 462-468
◽
2011 ◽
Vol 69
(3)
◽
pp. 763-771
◽